BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
    3.
    发明申请
    BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS 审中-公开
    作为磷酸二酯酶抑制剂的苯二酚或苯并二氧杂环己烷化合物

    公开(公告)号:US20150111915A1

    公开(公告)日:2015-04-23

    申请号:US14586681

    申请日:2014-12-30

    Applicant: LEO PHARMA A/S

    Abstract: Compounds of the general formula I wherein each of m and n is independently 0 or 1; R1 and R2, together with the carbon atom to which they are attached, form a heterocyclic ring comprising one or two heteroatoms selected from oxygen, sulfur, —S(O)— and —S(O)2—; R3 is —CHF2, —CF3, —OCHF2, —OCF3, —SCHF2 or —SCF3; X is a bond, —CH2—, or —NH—; A is aryl, cycloalkyl, cycloalkenyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkenyl, optionally substituted with one or more, same or different substituents selected from R4; and R4 is hydrogen, amino, thioxo, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, halogen, oxo, thia, or hydroxy; or pharmaceutically acceptable salts, hydrates or solvates thereof, have been found to exhibit PDE4 inhibiting activity, and may therefore be useful in the treatment of inflammatory diseases and disorders.

    Abstract translation: 通式I的化合物,其中m和n各自独立地为0或1; R1和R2与它们连接的碳原子一起形成包含一个或两个选自氧,硫,-S(O) - 和-S(O)2 - 的杂原子的杂环; R3是-CHF2,-CF3,-OCHF2,-OCF3,-SCHF2或-SCF3; X是键,-CH 2 - 或-NH-; A是任选被一个或多个相同或不同的选自R4的取代基取代的芳基,环烷基,环烯基,芳基烷基,杂芳基,杂芳基烷基,杂环烷基或杂环烯基。 R 4是氢,氨基,硫代,烷基,卤代烷基,羟基烷基,烷氧基,卤代烷氧基,卤素,氧代,硫杂或羟基; 已发现其药学上可接受的盐,水合物或溶剂化物表现出PDE4抑制活性,因此可用于治疗炎性疾病和病症。

    BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS

    公开(公告)号:US20160022657A1

    公开(公告)日:2016-01-28

    申请号:US14872487

    申请日:2015-10-01

    Applicant: LEO PHARMA A/S

    Abstract: Compounds of the general formula I wherein each of m and n is independently 0 or 1; R1 and R2, together with the carbon atom to which they are attached, form a heterocyclic ring comprising one or two heteroatoms selected from oxygen, sulfur, —S(O)— and —S(O)2—; R3 is —CHF2, —CF3, —OCHF2, —OCF3, —SCHF2 or —SCF3; X is a bond, —CH2—, or —NH—; A is aryl, cycloalkyl, cycloalkenyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkenyl, optionally substituted with one or more, same or different substituents selected from R4; and R4 is hydrogen, amino, thioxo, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, halogen, oxo, thia, or hydroxy; or pharmaceutically acceptable salts, hydrates or solvates thereof, have been found to exhibit PDE4 inhibiting activity, and may therefore be useful in the treatment of inflammatory diseases and disorders.

Patent Agency Ranking